ES2524966T3 - Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer - Google Patents

Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer Download PDF

Info

Publication number
ES2524966T3
ES2524966T3 ES09768290.0T ES09768290T ES2524966T3 ES 2524966 T3 ES2524966 T3 ES 2524966T3 ES 09768290 T ES09768290 T ES 09768290T ES 2524966 T3 ES2524966 T3 ES 2524966T3
Authority
ES
Spain
Prior art keywords
thieno
cancer
treatment
kinase inhibitors
pyridine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09768290.0T
Other languages
English (en)
Inventor
Michael R. Michaelides
Robin R. Frey
Michael L. Curtin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Bahamas Ltd
Original Assignee
AbbVie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Bahamas Ltd filed Critical AbbVie Bahamas Ltd
Application granted granted Critical
Publication of ES2524966T3 publication Critical patent/ES2524966T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Abstract

Un compuesto que tiene la Fórmula I **Fórmula** o una de sus sales terapéuticamente aceptables, donde R1 es hidroxialquilo; R2 se selecciona entre el grupo que consiste en alcoxi, alquilo, halo, y haloalcoxi; y R3 es hidrógeno o alquilo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20

Claims (1)

  1. imagen1
ES09768290.0T 2008-12-05 2009-12-04 Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer Active ES2524966T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US120281P 1999-02-16
US12028108P 2008-12-05 2008-12-05
US22376009P 2009-07-08 2009-07-08
US223760P 2009-07-08
PCT/US2009/066725 WO2010065825A2 (en) 2008-12-05 2009-12-04 Kinase inhibitors with improved cyp safety profile

Publications (1)

Publication Number Publication Date
ES2524966T3 true ES2524966T3 (es) 2014-12-16

Family

ID=41559043

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09768290.0T Active ES2524966T3 (es) 2008-12-05 2009-12-04 Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer

Country Status (26)

Country Link
US (2) US20100144783A1 (es)
EP (1) EP2373662B1 (es)
JP (1) JP5588458B2 (es)
KR (1) KR101639642B1 (es)
CN (1) CN102239171B (es)
AR (1) AR074481A1 (es)
AU (1) AU2009322270B2 (es)
BR (1) BRPI0921392A2 (es)
CA (1) CA2743592A1 (es)
CL (1) CL2011001312A1 (es)
CO (1) CO6382131A2 (es)
DO (1) DOP2011000153A (es)
EC (1) ECSP11011172A (es)
ES (1) ES2524966T3 (es)
HK (1) HK1159628A1 (es)
IL (1) IL212716A (es)
MX (1) MX2011005943A (es)
MY (1) MY179042A (es)
NZ (1) NZ592714A (es)
PA (1) PA8852401A1 (es)
PE (1) PE20110830A1 (es)
RU (2) RU2480472C2 (es)
TW (2) TWI500621B (es)
UA (1) UA103351C2 (es)
UY (1) UY32291A (es)
WO (1) WO2010065825A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
ES2524966T3 (es) * 2008-12-05 2014-12-16 Abbvie Bahamas Ltd. Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
SG186248A1 (en) * 2010-06-09 2013-01-30 Abbvie Inc Solid dispersions containing kinase inhibitors
CN103003283A (zh) * 2010-06-09 2013-03-27 Abbvie公司 激酶抑制剂的结晶形式
TWI492949B (zh) 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
US8911725B2 (en) 2010-06-23 2014-12-16 University Of Central Florida Research Foundation, Inc. Co-targeting of aurora A kinase and LIM kinase 1 for cancer therapy
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
US20150126545A1 (en) * 2011-12-14 2015-05-07 Abbvie Inc. Compositions containing kinase inhibitors
EP2885292A4 (en) * 2012-08-17 2015-07-01 Cancer Therapeutics Crc Pty Ltd VEGFR3 INHIBITORS
US9238644B2 (en) * 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
WO2015157360A1 (en) 2014-04-08 2015-10-15 Abbvie Inc. Processes to make protein kinase inhibitors
WO2015200635A1 (en) 2014-06-25 2015-12-30 Abbvie Inc. N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN114222729A (zh) * 2019-06-12 2022-03-22 范德比尔特大学 氨基酸转运抑制剂及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188529A (en) 1966-06-09 1970-04-15 Wellcome Found Pyramidine Derivatives
US4357535A (en) 1980-04-30 1982-11-02 North American Philips Corporation Apparatus for inspecting hand-held articles and persons carrying same
GB8307154D0 (en) 1983-03-15 1983-04-20 Mk Electric Ltd Terminals
US4767766A (en) 1987-01-30 1988-08-30 Merck & Co., Inc. Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0436810Y2 (es) 1987-12-29 1992-08-31
US4843949A (en) 1988-08-29 1989-07-04 Pneumo Abex Corporation Fluid control valve with variable pressure gain
GB8912498D0 (en) 1989-05-31 1989-07-19 De Beers Ind Diamond Diamond growth
EP0438261A3 (en) 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69431173T2 (de) 1993-06-16 2003-05-08 Du Pont Mit Wasser reinigbare Dickfilmpastenzusammensetzung
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
DE29511756U1 (de) 1995-07-20 1995-09-28 Ferco Int Usine Ferrures Flügelseitiges Ecklagerbeschlagteil für Drehkippfenster
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE19620508A1 (de) 1996-05-22 1997-11-27 Hoechst Ag Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2285424A1 (en) 1997-04-22 1998-10-29 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
CA2348740A1 (en) 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
DE60037455T2 (de) 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
ATE464740T1 (de) 2000-12-15 2010-04-15 British Telecomm Übertagung von ton- und/oder bildmaterial
DE60204674T2 (de) 2001-03-14 2006-05-18 Eli Lilly And Co., Indianapolis Retinoid x rezeptormodulatoren
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
JP2005508904A (ja) 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
US20050019424A1 (en) 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7265128B2 (en) 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10303311A1 (de) 2003-01-28 2004-07-29 Basf Ag Addukte auf Basis cyclischer Verbindungen und ihre Verwendung als Gerbstoffe und Konservierungsmittel
US7592352B2 (en) * 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008519862A (ja) 2004-11-11 2008-06-12 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｉｖ−１カプシド形成のインヒビター：置換アリール・アミノメチル・チアゾール尿素およびその類縁物質
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
US7566721B2 (en) 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
WO2007022280A1 (en) 2005-08-16 2007-02-22 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
US20080255184A1 (en) 2005-11-04 2008-10-16 Smithkline Beecham Corporation Thienopyridine B-Raf Kinase Inhibitors
JP5237108B2 (ja) * 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物
US20080021217A1 (en) 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
ES2524966T3 (es) * 2008-12-05 2014-12-16 Abbvie Bahamas Ltd. Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer

Also Published As

Publication number Publication date
IL212716A (en) 2013-10-31
CN102239171B (zh) 2014-06-11
KR101639642B1 (ko) 2016-07-14
US20120309783A1 (en) 2012-12-06
US8722890B2 (en) 2014-05-13
AU2009322270B2 (en) 2014-12-18
TWI441827B (zh) 2014-06-21
WO2010065825A3 (en) 2010-08-26
CN102239171A (zh) 2011-11-09
PA8852401A1 (es) 2010-07-27
UA103351C2 (uk) 2013-10-10
CA2743592A1 (en) 2010-06-10
IL212716A0 (en) 2011-07-31
RU2012156958A (ru) 2014-06-27
TWI500621B (zh) 2015-09-21
TW201431862A (zh) 2014-08-16
MY179042A (en) 2020-10-26
KR20110091577A (ko) 2011-08-11
US20100144783A1 (en) 2010-06-10
RU2480472C2 (ru) 2013-04-27
BRPI0921392A2 (pt) 2016-04-26
EP2373662A2 (en) 2011-10-12
AU2009322270A1 (en) 2011-07-14
UY32291A (es) 2010-07-30
TW201026706A (en) 2010-07-16
WO2010065825A2 (en) 2010-06-10
MX2011005943A (es) 2011-06-27
JP5588458B2 (ja) 2014-09-10
NZ592714A (en) 2013-03-28
RU2011127451A (ru) 2013-01-10
AR074481A1 (es) 2011-01-19
ECSP11011172A (es) 2011-08-31
HK1159628A1 (en) 2012-08-03
JP2012511016A (ja) 2012-05-17
CO6382131A2 (es) 2012-02-15
DOP2011000153A (es) 2011-06-30
EP2373662B1 (en) 2014-09-24
CL2011001312A1 (es) 2011-10-07
PE20110830A1 (es) 2011-12-14

Similar Documents

Publication Publication Date Title
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
AR053569A1 (es) Derivados de pirazol
ECSP088598A (es) Derivados de piridazinona
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
ECSP10010361A (es) Derivados de piridazinona
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
ECSP10010447A (es) Inhibidores de cinasa pim y métodos para su uso
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
NI201000059A (es) Inhibidores de la cinasa c-fms.
ES2546198T3 (es) Tratamiento contra la glomerulonefritis
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.